Ligand Pharmaceuticals Inc. (LGND)
Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech
Ligand Pharmaceuticals (LGND) is reassessed after a ~10% loss since its last 'Buy' rating. The article focuses on LGND's future prospects, emphasizing its key royalty producing assets. LGND is highlighted as a reliable midcap pharma with a high-growth business model.
Ligand Pharmaceuticals Q2 Earnings Call Highlights
Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator
Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Recent developments include a significant Xoma acquisition and portfolio advancements. I closely review LGND's Q1 2026 earnings, highlighting operational and financial performance and strategic moves.
Ligand Pharmaceuticals Q1 Earnings Call Highlights
Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million
Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company's royalty-focused business model and diversified portfolio as key drivers of continued earnings growth. Ligand provides capital and technology to drug and medical device developers in exchange for royalties, creating a portfolio of more than 100 commercial and development-stage assets that generate high-margin returns.
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Melanie Herman Todd Davis - CEO & Director Lauren Hay Octavio Espinoza - Chief Financial Officer Conference Call Participants Trevor Allred - Oppenheimer & Co. Inc., Research Division Jayed Momin - Stifel, Nicolaus & Company, Incorporated, Research Division Sahil Dhingra - RBC Capital Markets, Research Division Presentation Operator Thank you for standing by. Welcome to Ligand Third Quarter 2025 Earnings Call.
Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Lauren Hay - Corporate Participant Melanie Herman - Corporate Participant Octavio Espinoza - Chief Financial Officer Paul J. Hadden - Senior Vice President of Investments & Business Development Todd C.
